Evidence map›Paper›PMID 42577177›Full record

ReviewFrontiers in oncology2026

Multimodal AI fusion: integrating MRI with PET/CT, histopathology, and liquid biopsy for bone tumor diagnosis.

Guochao Li, Yayun Lin, Xueling Wang

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Guochao LiDepartment of Imaging, Yantaishan Hospital, Yantai, Shangdong, China.
Yayun LinDepartment of Ultrasonography, Yantaishan Hospital, Yantai, Shangdong, China.
Xueling WangDepartment of Imaging, Yantaishan Hospital, Yantai, Shangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diagnosis of bone tumors, though a low-incidence occurrence, presents a formidable challenge due to the morphological heterogeneity and variable biological behavior of these lesions. No single diagnostic modality whether imaging or biopsy is sufficient to provide the comprehensive information necessary for definitive diagnosis, accurate staging, and effective treatment planning. This report argues that a fragmented, sequential approach to diagnosis is inherently limited and that the future of orthopedic oncology lies in the integration of diverse data streams. Multimodal artificial intelligence (AI) offers a promising supportive approach by creating an AI-enabled integrative decision-support environment where computational systems can synthesize and contextualize information from magnetic resonance imaging (MRI), positron emission tomography computed tomography (PET/CT), histopathology, and liquid biopsy. This report details the specific capabilities and limitations of each of these foundational modalities, outlines the technical architectures required for their fusion, and illustrates how an integrated AI system can augment clinical workflows. It also addresses the critical challenges that must be overcome for clinical adoption, including data standardization, algorithmic interpretability, and economic viability, ultimately positioning this approach as an important emerging direction for future precision oncology.

Indexed as

AI−assisted decision supportbone tumor diagnosisdata integration in oncologydigital tumor boardmultimodal artificial intelligenceprecision oncologyprecision oncology workflow

Identifiers

PMID42577177
PMCPMC13453823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.